Transcriptional landscape associated with TNBC resistance to neoadjuvant chemotherapy revealed by single-cell RNA-seq
Radhakrishnan Vishnubalaji, Nehad M. Alajez
Abstract
) predictive of relapse-free survival (hazard ratio [HR]: 2.2 [1.6-3.2, p < 0.0001]) in a second cohort of 360 TNBC patients. Mechanistically, loss of function of several upregulated genes in the persistent group (BYSL, FDPS, ENO1, MED20, MRPL9, MRPL37, NDUFB11, PMVK, MYC, and GSTP1) inhibited MDA-MB-231 and BT-549 TNBC models' colony-forming unit (CFU) potential and enhanced their sensitivity to paclitaxel. Our data unraveled the transcriptional portrait associated with NAC resistance, identified several key genes, and suggested their potential utilization as prognostic markers and therapeutic targets in TNBC.
Topics & Concepts
Gene signatureCancer researchTriple-negative breast cancerTranscriptomeBiologyFOXM1Breast cancerCancerGeneDownregulation and upregulationGene expressionGeneticsCancer Cells and MetastasisSingle-cell and spatial transcriptomicsCancer Genomics and Diagnostics